TrialPath
Recruiting

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

NCT07721259 · University of Washington
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multiantigen Vaccine (STEMVAC) for Adjuvant Treatment of Patients With Moderate or Extensive Residual Triple-Negative Breast Cancer
About this study
OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid deoxyribonucleic acid (DNA) vaccine (STEMVAC) with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) intradermally (ID) every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial. ARM B: Patients receive GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial. After completion of study treatment, patients are followed up at 3 weeks after their last vaccination and then every 6 months for 3 years.
Eligibility criteria
Inclusion Criteria: * At least 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 * Triple-negative breast cancer as determined by the treating oncologist * Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist * Patients whose tumors progress on neoadjuvant therapy may be enrolled * No clinical evidence of local or distant recurrence * Plan to receive standard of care adjuvant directed therapy * Completed standard of care locoregional treatment, including definitive breast and lymph node surgery followed by standard radiation therapy, if recommended * Residual cancer burden (RCB) index 2 or 3 as calculated per routine anatomic pathology clinical standards * Absolute neutrophil count (ANC) ≥ 800/μL (within 30 days of first study vaccine administration) * Hemoglobin (Hgb) ≥ 8 g/dL (within 30 days of first study vaccine administration) * Platelets ≥ 75,000/ μL (within 30 days of first study vaccine administration) * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome, in whom total bilirubin must be \< 3.0 mg/dL (within 30 days of first study vaccine administration) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 1.5 x institutional ULN (within 30 days of first study vaccine administration) * Creatinine ≤ 1.5 x ULN mg/dL or creatinine clearance \> 60 mL/min (within 30 days of first study vaccine administration) * At least 28 days post systemic steroids prior to enrollment, unless used as part of prophylaxis to prevent intravenous (IV) contrast reactions. * Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed * Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment * Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a person of child-bearing potential. Acceptable methods of contraception are abstinence, condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal Exclusion Criteria: * Toxicities related to prior exposure to immune checkpoint inhibitors for which immune checkpoint inhibitors cannot be safely continued as determined by study investigator * Germline BRCA1 or BRCA2 mutations with adjuvant olaparib planned within the study period * NOTE: If olaparib is not planned, then these patients are eligible * Any known cardiac conditions: * Symptomatic restrictive cardiomyopathy * Dilated cardiomyopathy * Unstable angina within 4 months prior to enrollment * New York Heart Association functional class III-IV heart failure on active treatment * Symptomatic pericardial effusion * Autoimmune disease requiring active systemic treatment * Known hypersensitivity reaction to the GM-CSF adjuvant; any known contra-indication to GM-CSF * Pregnant or breast feeding * Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \[HBsAg\] reactive), or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] is detected) * Major surgery within the 4 weeks prior to initiation of first study vaccine * Enrollment in any other clinical protocol or investigational trial that involves concurrent administration of experimental therapy and/or therapeutic devices, or investigational drug. Patients who completed prior clinical trials (such as neoadjuvant treatment, surgery or radiation trials) and are on long term follow up are permitted
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-12-15
Estimated completion: 2030-07-16
Last updated: 2026-11-19
Interventions
Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineDrug: Recombinant Granulocyte-Macrophage Colony-Stimulating FactorProcedure: Biospecimen Collection
Primary outcomes
  • • Invasive breast cancer free survival (IBCFS) (Time from randomization to local or distant recurrence or death, assessed up to 3 years)
  • • Dynamics and characteristics of circulating tumor deoxyribonucleic acid (ctDNA) (Up to 3 weeks after last vaccination)
Sponsor
University of Washington · other
With: United States Department of Defense
Contacts & investigators
ContactResearch Coordinator(s) · contact · cvitrial@uw.edu · 866-932-8588
InvestigatorNatasha Hunter, MD · principal_investigator, Fred Hutch/University of Washington Cancer Consortium
All locations (1)
Fred Hutch/University of Washington Cancer ConsortiumRecruiting
Seattle, Washington, United States
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden · TrialPath